期刊文献+

化疗在复发子宫内膜癌治疗中的作用 被引量:2

Effects of chemotherapy in recurrent endometrial carcinoma
原文传递
导出
摘要 目的探讨化疗在复发子宫内膜癌患者治疗中的作用。方法对20例复发子宫内膜癌患者进行回顾性研究。主要分析内容为肿瘤的复发情况、复发后的治疗情况及化疗对预后的影响。结果复发患者20例,占同期内膜癌患者总数的11.0%。患者平均于初治后(17±10)个月复发。20例复发患者中11例(55.0%)接受化疗,平均(6±4)个疗程。再次治疗后,20例患者的平均随访时间为(17±16)个月,其中1例(5.0%)无瘤生存,4例(20.0%)带瘤生存,15例(75.0%)因癌死亡。单因素分析提示,是否接受化疗及化疗疗程数与患者预后明显相关(均P<0.05),是否放疗也与预后有关(P<0.05),而肿瘤病理类型、初次手术分期、肿瘤细胞分化程度、年龄和复发时间、是否手术、不同化疗方案、化疗给药途径及是否接受内分泌治疗与患者预后无关。多因素分析提示,复发后化疗对患者预后有显著影响(β=-1.349,OR=0.259,P<0.05)。结论综合治疗可以提高复发子宫内膜癌患者的生存率,化疗在其中起主导性作用,对患者预后有重要影响。 Objective To explore the effects of chemotherapy in recurrent endometrial carcinoma. Methods A retrospective study was carried out on the clinical data of 20 cases of recurrent endometrial carcinoma hospitalized from May. 1992 to Jura 2002. Results The recurrence rate of these 20 cases was 11.0%. The recurrence occurred (17 ± 10) months after the first therapy. Eleven of the 20 patients (55.0%) had accepted chemotherapy with (6 ±4) courses and were followed up for ( 17 ± 16) months after the second therapy. Fifteen cases (75.0%) died of cancer, 4 cases survived with tumor, and only 1 case (5.0%) was tumor-free. Univariate model revealed that chemotherapy and number of chemotherapy course were related with the prognosis (P = 0. 0146, P = 0. 0353 ). Radiotherapy o affected the prognosis too (P = 0.0414). But pathologic subtype, stage, tumor cell differentiation, age, recurrent time, surgery, chemotherapy scheme, drug infusion way , and endocrine therapy had no relation with the prognosis ( P =0. 5517, 0.5763, 0. 1879, 0. 880, 0. 453, 0. 0672, 0. 0795, 0. 5956, and 0. 2035). Multivariate model revealed that chemotherapy had influence on the prognosis (β = - 1. 349, OR = 0. 259, P = 0. 026 ). Conclusion Combined treatment raises the survival of the recurrent endometrial carcinoma patients, in which chemotherapy plays a leading role and influences the prognosis remarkably.
出处 《中华医学杂志》 CAS CSCD 北大核心 2006年第13期896-900,共5页 National Medical Journal of China
基金 "985"工程基金资助项目(985-2-015-24)
关键词 子宫内膜肿瘤 复发 预后 药物疗法 Endometrial Neoplasms Recurrence Prognosis Drug therapy
  • 相关文献

参考文献16

  • 1Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin,2005,55 : 10-30. 被引量:1
  • 2Mikuta JJ. International federation of gynecology and obstetrics staging of endometrial cancer 1988, Cancer, 1993,71:1460-1463. 被引量:1
  • 3Feltmate CM, Duska LR, Chang Y, et al. Predictors of recurrence in surgical stage Ⅱ endometrial adenocarcinoma. Gynecol Oncol,1999,73:407-411. 被引量:1
  • 4王建六,魏丽惠,薛凤霞,王志启.晚期子宫内膜癌20例复发转移特征及相关因素分析[J].中国实用妇科与产科杂志,2003,19(9):537-540. 被引量:8
  • 5屠铮,商宇红,富琪,王建六,魏丽惠.Ⅰ、Ⅱ期子宫内膜癌复发病例的特征与预后[J].中国妇产科临床杂志,2003,4(2):113-116. 被引量:3
  • 6Wylie J, Irwin C, Pintilie M, et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol,2000 ,77 :66-72. 被引量:1
  • 7杨永平,邓蕴华.29例复发性子宫内膜癌的临床分析[J].肿瘤防治杂志,2000,7(2):169-170. 被引量:2
  • 8Hall DJ, Martin DA, Kincaid K. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer:a clinical study and literature review. Eur J Gynaecol Oncol,2003,24:481-489. 被引量:1
  • 9Burke TW, Stringer CA, Meads M, et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin,doxorubicin, and cyclophosphamide. Gynecol Oncol,1991,40:264-267. 被引量:1
  • 10Fleming GF, Brunetto VL, Celia D, et al. Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol,2004,22:2159-2166. 被引量:1

二级参考文献36

共引文献13

同被引文献28

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部